IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti–IL-4 receptor α antagonist
RE Slager, BA Otulana, GA Hawkins, YP Yen… - Journal of Allergy and …, 2012 - Elsevier
BACKGROUND: This is the first large pharmacogenetic investigation of the inflammatory IL-
4/IL-13 pathway in patients with moderate-to-severe asthma. We analyzed genomic DNA
from participants in a 12-week placebo-controlled efficacy trial of pitrakinra (1, 3, or 10 mg
twice daily), a novel IL-4/IL-13 pathway antagonist (Clinicaltrials. govNCT00801853).
OBJECTIVES: The primary hypothesis for this analysis is that amino acid changes in the 3′
end of the IL-4 receptor α gene (IL4RA) or closely proximal variants would predict reductions …
4/IL-13 pathway in patients with moderate-to-severe asthma. We analyzed genomic DNA
from participants in a 12-week placebo-controlled efficacy trial of pitrakinra (1, 3, or 10 mg
twice daily), a novel IL-4/IL-13 pathway antagonist (Clinicaltrials. govNCT00801853).
OBJECTIVES: The primary hypothesis for this analysis is that amino acid changes in the 3′
end of the IL-4 receptor α gene (IL4RA) or closely proximal variants would predict reductions …